



# Massive Bio Nominated for Prestigious Digital Health Award

*Massive Bio has been named a Best in Class Quarterfinalist in the UCSF | Health Hub: Digital Health Awards competition.*

NEW YORK CITY, NY, USA, October 6, 2022 /EINPresswire.com/ -- Massive Bio has been named a quarterfinalist in the annual UCSF | Health Hub: Digital Health Awards, recognizing health tech companies driving innovation and improving healthcare delivery.

Massive Bio has been named a Best in Class Quarterfinalist in the UCSF | Health Hub: Digital Health Awards competition. These prestigious awards are granted annually by UCSF Health Hub (a non-profit organization affiliated with the University of California San Francisco) to recognize "the achievements of innovative health tech companies that are dramatically improving healthcare through the use of technology in the digital health industry."

More than 1,250 companies entered this year's UCSF | Health Hub: Digital Health Awards competition. Massive Bio was chosen by a panel of over 1,000 experts from industry and academia as one of 16 quarterfinalists in the "New Health Application of AI" category, which honors excellence in using artificial intelligence to improve the quality, reliability, and cost-efficiency of healthcare. Massive Bio's unique artificial intelligence-driven platform, SYNERGY-AI, rapidly matches cancer patients to clinical trials of promising new oncology therapies. The company's mission is to remove barriers to clinical trials for patients needing advanced treatments and increase the efficiency of drug development for the pharmaceutical industry.

"This nomination represents an important milestone for Massive Bio, being recognized as a major player in the digital health space at a global level, and we are honored and humbled to be listed amongst the 'best in class in the industry,'" said Arturo Loaiza-Bonilla, MD, Massive Bio co-founder, and chief medical officer. "Our AI-enabled technology is well positioned to optimize clinical workflows, advancing precision medicine and novel approaches to oncology research such as just-in-time, decentralized clinical trials, and digitally enabled patient-centric solutions. This recognition greatly validates our approach and current and potential impact."

"This recognition is a testament to the hard work of all our team and those who believe in our mission to make clinical trials accessible to all cancer patients," added Selin Kurnaz, co-founder and CEO of Massive Bio. "We want to make sure this novel, the scalable use case of AI helps patients across the globe find personalized clinical trial options, in real-time, to treat their

cancer.”

Finalists for the UCSF | Health Hub: Digital Health Awards will be announced on October 21, with the winners revealed at the grand finale of the 2022 HLTH conference in Las Vegas on November 14.

Learn more about the UCSF | Health Hub: Digital Health Awards [here](#).

#### About Massive Bio

Founded in New York City in 2015, Massive Bio aims to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances. Massive Bio solves bottlenecks in recruiting patients for clinical trials with a unique technology-enabled service and big data platform. The company serves pharmaceutical companies, contract research organizations (CROs), and hospital networks with a focus on improving the lives of cancer patients and provides oncology-specific, data-driven patient recruitment, site selection, and AI-based trial pre-screening services.

Massive Bio was awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize the Deep Learning Clinical Trial Matching System (DLCTMS) and is the official matching partner in all NCI-funded clinical trials. The company is also an active participant in the Integrated Trial Matching for Cancer Patients and Providers team led by MITER and the American Cancer Society Cancer Action Network.

Massive Bio has received investments totaling \$18 million since its establishment. The company has 75 employees, partners with 26 pharmaceutical companies and CROs, and more than 1,000 global clinical research centers in 12 countries. Massive Bio, which has reached more than 66,000 patients in clinical trial matching, aims to grow that total to 100,000 cancer patients by expanding to 19 countries with its "100K Cancer Clinical Trial Singularity Program," announced in 2021.

You can reach Massive Bio via [100KSINGULARITY@massivebio.com](mailto:100KSINGULARITY@massivebio.com), Twitter, LinkedIn, and Facebook.

#### About Arturo Loaiza-Bonilla, MD MEd

Arturo Loaiza-Bonilla, MD, MEd, is the co-founder and chief medical officer at Massive Bio, a global industry leader in connecting patients to clinical trials using artificial intelligence. An internationally renowned medical oncologist and researcher, Dr. Loaiza-Bonilla has a distinguished academic and clinical career in precision medicine oncology, immunotherapy, clinical trial design, digital health, entrepreneurship, and patient advocacy. Dr. Bonilla is board certified in both medical oncology and hematology, has extensive experience in the diagnosis and treatment of genomic biomarker-driven cancers, and serves as enterprise Medical Director of Oncology Research at Capital Health.

Dr. Loaiza-Bonilla earned a medical degree from the Universidad Nacional de Colombia in Bogotá, Colombia. Following medical school, he completed an internship and residency in internal medicine at Harbor Hospital Center and Johns Hopkins Hospital in Baltimore, Maryland. Dr. Loaiza-Bonilla also completed a fellowship in hematology and oncology from the University of Miami, Miller School of Medicine in Miami, Florida. He completed his master's degree in medical education at the University of Pennsylvania and pursued professional certification in Artificial Intelligence in healthcare at the MIT Sloan School of Management.

Before joining Capital Health, Dr. Loaiza-Bonilla was vice chairman of the Department of Medical Oncology at Cancer Treatment Centers of America in Philadelphia, Pennsylvania, as well as enterprise director of research, where he provided leadership and expertise to their oncology trial portfolio across five cancer centers and over 70 National Clinical Trials Network and industry-sponsored clinical trials. His research has been extensively published in the most prominent journals and meetings in oncology, and he has been the recipient of NIH funding to advance digital health and artificial intelligence tools for cancer research. He was also an assistant professor of Clinical Medicine at the University of Pennsylvania School of Medicine and is currently an associate professor in the Department of Medicine at Drexel University College of Medicine, both in Philadelphia.

Merve Sahin

Massive Bio

+90 533 564 99 65

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/594478416>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.